torvacard neo 60mg potahovaná tableta
zentiva, k.s., praha array - 14884 trihydrÁt vÁpenatÉ soli atorvastatinu - potahovaná tableta - 60mg - atorvastatin
torvacard neo 80mg potahovaná tableta
zentiva, k.s., praha array - 13790 atorvastatin - potahovaná tableta - 80mg - atorvastatin
torvazin 10mg potahovaná tableta
egis pharmaceuticals plc, budapešť maĎarsko - 16464 vÁpenatÁ sŮl atorvastatinu - potahovaná tableta - 10mg - atorvastatin
torvazin 20mg potahovaná tableta
egis pharmaceuticals plc, budapešť maĎarsko - 16464 vÁpenatÁ sŮl atorvastatinu - potahovaná tableta - 20mg - atorvastatin
torvazin 40mg potahovaná tableta
egis pharmaceuticals plc, budapešť maĎarsko - 16464 vÁpenatÁ sŮl atorvastatinu - potahovaná tableta - 40mg - atorvastatin
tulip 40mg potahovaná tableta
lek pharmaceuticals d.d., ljubljana array - 16464 vÁpenatÁ sŮl atorvastatinu - potahovaná tableta - 40mg - atorvastatin
tulip neo 10mg potahovaná tableta
lek pharmaceuticals d.d., ljubljana array - 14884 trihydrÁt vÁpenatÉ soli atorvastatinu - potahovaná tableta - 10mg - atorvastatin
tulip neo 20mg potahovaná tableta
lek pharmaceuticals d.d., ljubljana array - 14884 trihydrÁt vÁpenatÉ soli atorvastatinu - potahovaná tableta - 20mg - atorvastatin
pylclari
curium pet france - piflufolastat (18f) - prostatetické novotvary - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).